The global hormone replacement therapy (HRT) market is projected to reach USD 35.60 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.6% from 2023 to 2030, according to a new study by Grand View Research Inc. This market expansion is primarily driven by the rising prevalence of hormonal disorders and advancements in drug delivery systems. For instance, approximately 70,000 individuals in the U.S. suffer from hypoparathyroidism, a condition involving hormone imbalances, according to the National Organization of Rare Diseases.A significant factor contributing to the market growth is the ongoing technological improvements aimed at reducing side effects and increasing the bioavailability of hormone therapy drugs. Higher bioavailability allows for more effective treatments, which can, in turn, reduce the frequency of administration. For example, products like NGENLA, designed to treat growth hormone deficiencies, only require a once-a-week dosage, thereby improving patient compliance with treatment regimens. Moreover, improvements in drug administration routes are anticipated to further enhance market adoption. Intranasal estrogen medications, such as Nafarelin, offer greater patient compliance compared to traditional oral or injection methods, especially among women, due to their convenience and ease of use.
Pharmaceutical companies are adopting strategies such as partnerships and collaborations to expand their market presence and drive revenue growth. A notable example is Merck & Co., Inc.’s agreement with BIOCORP in September 2021 to develop and distribute the HGH monitoring device, Mallya. This device helps in tracking daily human chorionic gonadotropin (HCG) treatment, which is essential for various hormone-related conditions. Such initiatives are expected to support market growth throughout the forecast period.
Additionally, the introduction of new hormone replacement therapy medications is set to further fuel the market. For instance, in November 2021, Fuji Pharma Co., Ltd. launched F-meno (100 mg capsule) to prevent endometrial hyperplasia in patients undergoing estrogen therapy for menopausal disorders.
Hormone Replacement Therapy Market Highlights
Based on the product, the estrogen & progesterone replacement therapy segment held the highest market share of 54.34% in 2022 and is estimated to maintain its dominance during the forecast period due to high demand due to the increasing number of women reaching menopause
Parathyroid hormone replacement therapy is anticipated to witness the fastest growth during the forecast period due to the rising adoption of hormone replacement for the treatment of hypoparathyroidism
Based on the route of administration, the oral segment dominated the market with a share of 42.48% in 2022 owing to the high prescription rate. Around 120 million prescriptions of Levothyroxine sodium tablets are being dispensed annually in the U.S
List of Key Players of Hormone Replacement Therapy Market
Eli Lilly and Company
Bayer AG
Noven Pharmaceuticals, Inc.
Pfizer Inc.
Merck & Co., Inc.
Viatris, Inc.
Novo Nordisk A/S
F. Hoffmann-La Roche Ltd.
Order a free sample PDF of the Hormone Replacement Therapy Market Intelligence Study, published by Grand View Research.